21 completed, 5 terminated, 2 active not recruiting, 1 unknown. 14 Phase 1, 10 Phase 2, 6 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 10, Terminated 3, Active not recruiting 1 |
| Phase 2 | 10 | Completed 4, Terminated 4, Active not recruiting 2 |
| Phase 3 | 6 | Completed 6 |
| Not applicable | 1 | Withdrawn 1 |
Follow Dynavax Technologies Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age rF1V-1018 - Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis | Phase 2 | Active not recruiting | Dynavax Technologies Corporation | 148 | 2025-09-11 | 2026-10-05 |
| Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over Z-1018, Shingrix - Shingles, Herpes Zoster | Phase 1 / Phase 2 | Active not recruiting | Dynavax Technologies Corporation | 764 | 2024-06-17 | 2026-10-16 |
| Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age rF1V-1018, rF1V vaccine - Plague, Pneumonic, Plague | Phase 2 | Completed | Dynavax Technologies Corporation | 200 | 2022-08-09 | 2025-07-29 |
| Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers Z-1018, Shingrix - Shingles, Herpes Zoster | Phase 1 | Completed | Dynavax Technologies Corporation | 150 | 2022-01-10 | 2022-11-07 |
| DV2-HBV-27: Observational Pregnancy Registry HEPLISAV-B - Pregnant | Unknown | Dynavax Technologies Corporation | 300 | 2021-02-21 | 2023-09-18 | |
| B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B HEPLISAV-B, ENGERIX-B - HIV Infection, Hepatitis B | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 638 | 2020-12-14 | 2025-07-20 |
| Use of Dynavax Heplisav B in Healthcare Workers Previously Vaccinated With 3-dose Vaccine Who Failed to Demonstrate Seroprotection Adjuvanted Hepatitis B Vaccine - Hepatitis B Virus | Not applicable | Withdrawn | University of Louisville | 2020-06-01 | 2021-04-30 | |
| Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults BG505 SOSIP.664 gp140, Placebo, 3M-052-AF - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 127 | 2020-01-13 | 2025-09-02 |
| SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer Nivolumab, Radiation Therapy, TLR9 Agonist SD-101 - Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma | Phase 1 | Completed | University of California, Davis | 6 | 2019-08-15 | 2023-08-01 |
| HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis HEPLISAV-B® - End Stage Renal Disease on Hemodialysis (Diagnosis) | Phase 1 | Completed | Dynavax Technologies Corporation | 119 | 2019-04-22 | 2024-08-09 |
| Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC DV281, Breath Actuated Nebulizer, DV281 (RP2D) - Advanced Non Small Cell Lung Cancer | Phase 1 | Completed | Dynavax Technologies Corporation | 26 | 2017-09-20 | 2020-06-17 |
| A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma SD-101(1), Pembrolizumab, SD-101(2) - Metastatic Melanoma, Head Neck Cancer | Phase 1 / Phase 2 | Terminated | Dynavax Technologies Corporation | 241 | 2015-09-01 | 2021-08-03 |
| Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma SD-101, Radiation therapy - B-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Dynavax Technologies Corporation | 29 | 2014-10-01 | 2020-09-04 |
| Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine HEPLISAV, Engerix-B - Healthy | Phase 3 | Completed | Dynavax Technologies Corporation | 8374 | 2014-04-01 | 2019-03-20 |
| A Study of the Immune Response to Heplisav in Healthy Older Adults HEPLISAV - Hepatitis B | Phase 1 | Completed | Dynavax Technologies Corporation | 25 | 2013-11-01 | 2019-03-20 |
| Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis HEPLISAV, Engerix-B, Fendrix - End Stage Renal Disease | Phase 3 | Completed | Dynavax Technologies Corporation | 155 | 2010-12-01 | 2019-03-20 |
| Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease HEPLISAV, Engerix-B - Chronic Kidney Disease | Completed | Dynavax Technologies Corporation | 147 | 2010-12-01 | 2019-03-20 | |
| Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine HEPLISAV and/or Placebo, Engerix-B - Healthy | Phase 3 | Completed | Dynavax Technologies Corporation | 2452 | 2010-02-01 | 2019-03-20 |
| Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients HEPLISAV-B, Engerix-B, Placebo - Chronic Kidney Disease | Phase 3 | Completed | Dynavax Technologies Corporation | 521 | 2009-09-01 | 2021-05-19 |
| A Study to Assess DV-601 in Subjects With Chronic Hepatitis B DV-601, Entecavir - Hepatitis B, Chronic | Phase 1 | Completed | Dynavax Technologies Corporation | 14 | 2009-09-01 | 2019-04-16 |
Showing 20 of 30. Sign in to see all of them.
Hepatitis B (15) · Hepatitis (9) · Kidney Failure, Chronic (5) · Renal Insufficiency, Chronic (4) · Renal Insufficiency (3) · Vaccine-Preventable Diseases (3) · HIV Infections (2) · Herpes Zoster (2) · Hypersensitivity (2) · Neoplasms (2) · Rhinitis, Allergic, Seasonal (2) · Carcinoma (1) · Colorectal Neoplasms (1) · Disease (1) · Head and Neck Neoplasms (1)
Hepatitis B Vaccines (10) · Engerix-B (8) · Heplisav-B (5) · 1018 oligonucleotide (2) · Nivolumab (2) · Radiotherapy (2) · DV281 (1) · Fendrix (1) · Histamine (1) · Nebulizers and Vaporizers (1) · Radiation (1) · Ribavirin (1) · Rituximab (1) · Sodium Chloride (1) · aluminum sulfate (1)
United States (21) · Canada (4) · Australia (3) · Germany (3) · New Zealand (2) · Poland (2) · Botswana (1) · Brazil (1) · Kenya (1) · Malawi (1) · Philippines (1) · South Africa (1) · Thailand (1) · Uganda (1) · Vietnam (1)
Eduardo Martins, MD, DPhil (5) · Abraham Leung, MD (1) · Antoni Ribas, MD (1) · Arnold Freedman, MD (1) · Dennis Ruff, MD (1) · Eduardo Martins, MD, D Phil (1) · Edward Garon, MD (1) · Edward J Kim, MD, PhD (1) · Ezra Cohen, MD (1) · J. Tyler Martin, Sr, MD (1) · Janusz Cianciara, MD (1) · Kenneth E. Sherman, MD, PhD (1) · Kristen Marks, MD (1) · M. Juliana McElrath (1)
PMID 20412135, PMID 23727002, PMID 23727422, PMID 29289383, PMID 30154193, PMID 31431412, PMID 34780125, PMID 37017075, PMID 37085451, PMID 37781954, PMID 39616603, PMID 40147293
2009 (2), 2008 (1), P30CA093373 (1)